{
  "name" : "dacemirror.sci-hub.se_journal-article_dc5e78cf0fd1d11a211b42c43d24ade8_cheng2019.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "Rapid and Sensitive Nano-Immunosensors for Botulinum",
    "authors" : [ "Hui-Pin Cheng", "Han-Sheng Chuang" ],
    "emails" : [ ],
    "sections" : [ {
      "heading" : null,
      "text" : "KEYWORDS: botulinum, foodborne toxin, SNAP-25, AuNPs, diffusivity, immunosensor\nFoodborne diseases caused by bacterial toxins in food andenvironmental samples, especially food toxins that can trigger serious health concerns and easily endanger our vulnerable healthcare system, are an immense threat to public health.1−3 On-site monitoring of the food industry and medical instrument hygiene is imperative to ensure zero contamination during manufacturing and storage.4,5 Bacterial toxins, such as aflatoxin, botulinum toxin, and ocher aflatoxin, are environmentally stable and can exist in nature for long periods without degradation.6 Botulinum neurotoxin (BoNT) produced by Clostridium botulinum is the most prevalent cause of foodborne diseases worldwide.7−9 BoNT has attracted more attention compared with other toxic pathogens because of its lethal dose (∼1 ng/kg) in unvaccinated humans. However, its potent toxicity also enables its controlled use in medical and cosmetic treatments.10−12 BoNT is structurally composed of heavy and light chains with a total molecular weight of approximately 150 kDa. BoNT can be classified into seven serotypes (A−G)13,14 based on the segments it targets in neurons. The toxicity of all BoNT serotypes involves inhibition of synaptic vesicle docking and fusions by cleaving synaptosomal-associated proteins.15,16 This inhibitive reaction may kill living animals by weakening their vital organs when the toxin enters the digestive system. The same reaction can be used to prevent skin wrinkles when the injection spots and dose are systematically controlled. Early detection of BoNTs in patients or the food processing industry is vital because botulinum is a rare but highly fatal pathogen. While conventional detection approaches, including\nhigh-performance liquid chromatography,17 mass spectrometry,18 and colorimetric Enzyme-Linked ImmunoSorbent Assays (ELISAs),19,20 have been developed, the U.S. Food and Drug Administration (FDA) maintains that mouse lethality assay is the gold standard of BoNT detection.21,22 Unfortunately, mouse assay requires 7−14 days to complete, is expensive, and has sparked ethical controversy. Other methods require tedious processes. To address this problem, highly sensitive cell-based assays were recently adopted to quantitatively detect biotoxin activity in pharmaceutical products.23 However, cell lines exhibit sensitivities far lower than that required to detect clinical BoNT preparations. Besides conventional cell-based assays, various bead-based immunosensors, which feature low cost, flexibility, simplicity, and high sensitivity, have also been investigated for trace target analysis. Hatch et al.,24 for example, developed a rapid diffusion immunoassay on a Tsensor to measure phenytoin concentrations as low as 0.43 nM in less than 1 min. A similar T-shaped microchannel combined with a magnet was proposed and theoretically analyzed by Forbes et al.;25 simulations indicated that the integration improved the sensitivity and response time of the resulting sensor compared with those of pure antigen/antibody interactions. Gaster et al.26 monitored the kinetics of protein interactions on a high-density giant magnetoresistive (GMR)\nReceived: April 4, 2019 Accepted: May 30, 2019 Published: May 30, 2019\n© XXXX American Chemical Society A DOI: 10.1021/acssensors.9b00644 ACS Sens. XXXX, XXX, XXX−XXX\nD ow\nnl oa\nde d\nvi a\nU N\nIV O\nF SO\nU T\nH E\nR N\nI N\nD IA\nN A\no n\nJu ly\n2 0,\n2 01\n9 at\n0 2:\n50 :3\n2 (U\nT C ). Se e ht tp s: //p ub s. ac s. or g/ sh ar in gg ui de lin es f or o pt io ns o n ho w to le gi tim at el y sh ar e pu bl is he d\nar tic\nle s.\nbiosensor array and determined the binding kinetics (20 zmol) of epithelial cell adhesion molecule antibody−antigen using the proposed GMR technique. Gupta et al.27 reported a Agenhanced immunoassay using Au nanoparticles (AuNPs) based on optical densitometry. The LOD of this technique was 0.1 μg/cm3 (total of 4 ng of antigen), and, after Ag enhancement, signals could even be visualized by the naked eye. Considering the potential of bead-based sensors, we propose a diffusometry-enabled bead-based sensing technique,28−32 hereinafter referred to as nano-immunosensors, to achieve the rapid, simple, and quantitative detection of biological toxins for on-site monitoring in clinics or the food industry. Diffusion refers to random movement driven by Brownian motion, which is directly associated with the ambient temperature, viscosity, and particle diameter. Diffusivity is used as a quantitative signal to reveal the real-time binding activity between the nano-immunosensors and target proteins. In principle, Brownian motion declines with increasing particle volume because toxic proteins bind to nanosized particles. Thus, high toxin concentrations will suppress Brownian motion. The technique can be extended to the simultaneous detection of multiple toxins in the same process. Considering that most foodborne disease outbreaks and cosmetic surgery infections are primarily attributed to type A BoNT (BoNT/A), this toxin was selected as the target toxin for the present study. The applicability of the proposed sensor to detect BoNT/A concentrations ranging from 0.01 to 500 ng/mL in milk, serum, and phosphate buffered saline (PBS) was investigated. A short measurement time (2 min), including image acquisition and focusing, and an LOD of 10 pg/mL were achieved. The activity of BoNT/A was evaluated using SNAP25 antibody, and results were confirmed by using standard mouse assay.21 The contributions of this study include (1) development of a novel nano-immunosensor for the selective detection of BoNT/A (Scheme 1); (2) quantification of diffusivity determined by the pro A complete nano-\nimmunosensor posed bead-based immunoassay with a spatial cross-correlation algorithm; and (3) investigation of toxin concentration/activity, LOD, and sensitivity.\n■ EXPERIMENTAL SECTION Materials and Reagents. Yellow-green fluorescent particles (200 nm) with carboxylate-modified surfaces (F8764) were purchased from Thermo Fisher Scientific Inc. (Waltham, MA). BoNT/A toxic protein, i.e., botulinum neurotoxin type A toxoid from C. botulinum (133 L), was purchased from List Biological Laboratories, Inc. (Campbell, CA). Monoclonal mouse anti-BoNT/A IgG (KBA211), which was used as a capture antibody for protein quantification, was purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Monoclonal mouse anti-SNAP-25 IgG types 111111 and 111011, which were respectively used as the capture and probe antibodies to detect toxin activity, were purchased from Synaptic Systems (Göttingen, Germany). Polyclonal mouse anti-BoNT/A IgG (MAB4489), which was used as a probe antibody, was purchased from R&D Systems (Minneapolis, MN). N-Hydroxysuccinimide (NHS, A1031236) and N-ethyl-N′-(3-(dimethylamino) propyl)carbodiimide (EDC, A10807) were purchased from Alfa Aesar (Ward Hill, USA). Spherical AuNPs (80 nm) (ab154876) were purchased from Abcam (Cambridge, UK). BOTOX and Dysport, two commercial BoNT/A products, were purchased from Allergan Inc. (Irvine, CA) and Ipsen Corp. (Slough, UK), respectively. PBS (10×) (UR-PBS001) was purchased from UniRegin Bio-Tech (Taoyuan, Taiwan). Tween 20 (P5927), 2-(N-morpholino) ethanesulfonic acid (MES, M3671), and bovine serum albumin (BSA) were purchased from Sigma-Aldrich (St. Louis, MO).\nPreparation of Nano-Immunosensors. For protein detection, sandwiched immunocomplexes were designed on probe particles to form the so-called “nano-immunosensors”. A complete nanoimmunosensor was composed of a fluorescent probe particle, monoclonal antibody, BoNT/A, polyclonal antibody, and AuNPs. Carboxylate-modified particles (200 nm) (yellow-green fluorescence) were diluted in PBS and Tween (PBST) and readjusted to a concentration of 4.54 × 1012 particles/mL. The suspension of fluorescent particles (200 μL) was conjugated with monoclonal mouse anti-BoNT/A IgG to detect BoNT/A toxic protein. The monoclonal antibody was replaced with monoclonal mouse anti-\nScheme 1. Conceptual Illustration of the Immunosensing Platform to Detect Toxin Protein and Activity in Complex Matricesa\naSteps 1−2: Anti-BoNT/A or SNAP-25 antibodies were conjugated with Au NPs. Step 3: During particle incubation with toxin-containing samples, antibodies conjugated with AuNPs were mixed in the same vial, and the final sandwiched immunocomplex was formed. Step 4: Toxin concentration or activity was determined by using a microscopic imaging system based on a cross-correlation algorithm to quantitate the degree of Brownian motion.\nDOI: 10.1021/acssensors.9b00644 ACS Sens. XXXX, XXX, XXX−XXX\nB\nSNAP-25 IgG to detect toxin activity. Carboxylic acid groups on the fluorescent probe particles were activated by 4 μL of 10 μg/μL NHS and 2 μL of 10 mg/mL EDC at 25 °C in a shaker for 20 min. MES was then used as a coupling buffer. Subsequently, 10 μL of the capture antibody (0.1 μg/μL) was mixed with the colloidal suspension and incubated at 4 °C for 4 h. The mixture was purified through four cycles of centrifugal washing with PBST at 13,500 rpm to remove excess suspended antibodies. PBST was prepared by mixing 0.01% Tween 20 in 1× PBS. The functionalized probe particles were blocked with 1% BSA at 4 °C for 30 min to avoid nonspecific binding. Subsequently, the suspension was centrifuged four times in PBST at 13,500 rpm to remove excess BSA and resuspended in PBST to achieve a final volume of 200 μL. To prepare different sample matrices, 3% milk and 1% BS were obtained by diluting their powder forms with PBS to reduce their viscosity. No substantial differences in diffusivity between sample matrices were observed. To achieve a sandwiched configuration, we separately used two 25 μL aliquots of 0.1 μg/μL probe antibodies, polyclonal mouse antiBoNT/A IgG, and monoclonal mouse anti-SNAP-25 IgG targeting the light chain of BoNT/A to detect toxic proteins and SNAP-25 to detect toxin activity. Next, 80 nm AuNPs (3 μL) were attached to the two probe antibodies following the manufacturer’s protocol included in the Au conjugation kit. Considering that the antibodies and proteins are small enough to avoid causing significant changes in diffusivity compared with the main fluorescent particles, AuNPs were used to amplify the size effect of Brownian motion. The final sandwiched immunocomplexes were established by mixing and incubating the functionalized capture particles, antibody-conjugated AuNPs, and toxin proteins at 25 °C in a shaker for 1 h. The diffusivity of the immunocomplexed particles declined as the concentration of toxic proteins increased in the sample. In light of the activity of the toxins, however, the diffusivity of the immunocomplexed particles declined as the concentration of active toxins increased in the sample. Diffusometry-Enabled Nano-Immunosensors for BoNT/A. Given that Brownian motion is a function of temperature, medium viscosity, and particle diameter,33 diffusivity decreases with increasing particle volume when all other parameters are well controlled. Thus, the concentration of BoNT/A can be measured from changes in diffusivity. In this study, the probe particle volume progressively increased with increasing attachment of BoNT/A protein to the particles. Diffusivity was quantified by using a spatial cross-correlation algorithm.34 The width of a correlation function represents the extent of particle diffusion in a static medium. The relationship between diffusivity and the correlation function is written as follows:34\n∝ Δ − Δ\nΔ D S t\nSc a 2 2\n(1)\nwhere ΔSa and ΔSc denote widths of autocorrelation and crosscorrelation peaks, respectively; and Δt is the time interval between image frames.\nAmong the eight defined serotypes of BoNT, type A (BoNT/A) was selected as the target toxic protein for our nano-immunosensors because it is a frequent cause of food poisoning. Different concentrations of samples ranging from 0.001 ng/mL to 500 ng/ mL were prepared and incubated at 4 °C with a suspension containing the capture antibody-functionalized particles and antibodyconjugated AuNPs. The final sandwiched immunocomplexes were formed in the presence of BoNT/A (Figure 1A). The concentration of toxic proteins in the medium was determined by the diffusivity of the immunocomplexed probe particles. The activity of toxic proteins in the medium was measured in the same manner except that antiBoNT/A antibodies were replaced with anti-SNAP-25 antibodies (Figure 1B).\nMeasurement Platform. All data were measured by using a microscopic imaging system comprising an upright microscope (BX51, Olympus) equipped with a filter cube (UMWB2, Olympus), a 20× objective (UPlanFL N, Olympus), and a digital camera (FL3U3−13S2C−CS, Point Gray). During measurement, 2 μL of colloidal suspension was pipetted onto a glass slide and covered with a glass cover separated by a 165 μm spacer. To enable diffusion, we set the focal plane in the middle depth of the sample drop. A total of 200 particle images were consecutively captured at a 15 Hz frame rate and room temperature. The consecutive images were analyzed using the cross-correlation algorithm to obtain the quantitative degree of Brownian motion−diffusivity. The detailed computational procedure is discussed in our prior studies.34 In all experiments, negative-control samples were run in either triplicate or nonuplicate (when LOD determinations were conducted) to monitor for nonspecific protease contamination.\nVerification with ELISA. In this study, ELISA was used to verify our measurements using the proposed nano-immunosensors. Capture and detector antibodies against BoNT/A were used to measure the concentration of the toxin in pharmaceutical preparations of BoNT/A toxoid. The plates were coated with antibotulinum toxin A diluted 1:1000 in PBS and stored overnight at 4 °C. After coating, the plates were washed with PBST and blocked with 3% dry skim milk. BoNT/ A toxoids at different concentrations (1−500 ng/mL) were added to this solution, and the resulting mixture was incubated for 1 h at 37 °C. After washing, the detector antibody was added, and the mixture was\nDOI: 10.1021/acssensors.9b00644 ACS Sens. XXXX, XXX, XXX−XXX\nC\nincubated for 1 h at 37 °C. The conjugate antibody was added to each well of the plate. 2,2′-Azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt peroxidase substrate was added, and the mixture was incubated once more for 30 min at 37 °C. Product absorbance was measured at 405 nm by using a microplate reader (Multiskan FC, Thermo Fisher Scientific), and results were expressed as relative absorbance units. BoNT/A Activity Assay. The present study compared the enzymatic activities of two commercial BoNT/A products, namely, BOTOX and Dysport. The two products were handled in compliance with their manufacturers’ protocols and diluted in 1 mL of digestion buffer containing 50 mM HEPES (pH 7.4), 5 mM NaCl, 0.1% Tween 20, 0.05% ZnCl2, and 2 mM DTT. Assays were initiated by adding 30 μL of SNAP-25-conjugated particles mixed with 200 μL of BoNT/A drug products in digestion buffer and then incubating the resulting mixture at 30 °C for 3 h. After digestion, 30 μL of 5% trifluoroacetic acid was added to stop the reaction. The microbeads were washed thrice with 200 μL of PBST, mixed with SNAP-25 cleavage antibodies conjugated with AuNPs, and incubated at 25 °C in a shaker for 1 h. The final immunocomplexes were formed, and the samples were analyzed by measuring their diffusivity.\n■ RESULTS AND DISCUSSION Validation of the Bead-Based Immunoassay with Conventional ELISA. Conventional ELISA assays with multiwell microplates have been recommended by the FDA and are routinely applied to identify and detect toxins or proteins. In this study, conventional ELISA was used to provide certified data for comparison with our bead-based immunoassay. Serial dilutions of BoNT/A with PBS to achieve\nfinal toxin concentrations of 1−500 ng/mL were simultaneously evaluated by microplate ELISA and the proposed nano-immunosensors. Microplate ELISA could only resolve toxin concentrations above 6.9 ng/mL (Figure 2A), whereas our nano-immunosensors could achieve an LOD of less than 1 ng/mL (Figure 2B). LODs were determined by the intersection of the slope of relative diffusivity and the upper limit obtained from three standard deviations (SDs) of the control (without BoNT/A). Comparisons indicated that highly sensitive and reliable toxin detection could be achieved using bead-based diffusometry.\nDetection of Botulinum Toxins in Different Matrices. Considering that botulinum toxins in actual conditions may appear in various media, the specificity and robustness of the proposed nano-immunosensors were evaluated. In addition to PBS, two buffers commonly used in medical inspection and food, namely, serum and milk, were selected as major suspending matrices for BoNT/A. The functionalized particles and AuNPs were incubated in different BoNT/A concentrations. In this study, BoNT/A was detected in all sample matrices, and diffusivity changed in a dose-dependent manner (Figure 3A). A high dose implies a large particle diameter. Thus, diffusivity decreased with increasing BoNT/A concentration. The relative diffusivity decreased by 2.2-fold from 1 ng/mL to 500 ng/mL. All colloidal suspensions were frequently vortexed and sonicated during preparation and before measurement to avoid aggregation. Thereafter, the particles were well dispersed in all media, and no serious\nDOI: 10.1021/acssensors.9b00644 ACS Sens. XXXX, XXX, XXX−XXX\nD\naggregation was observed (Supporting Information Figure S1). Several particle images were analyzed by using the spatial cross-correlation algorithm, which yielded a statistical distribution and dubbed correlation function representing the extent of random motion of overall particles. Thus, the result was not altered by a few minor aggregates. We evaluated the nano-immunosensor’s LOD in milk or serum at toxin concentrations of 100 ng/mL to 1 pg/mL. Based on the calibration curves for BoNT/A in serum and milk, the LOD of the proposed assay was approximately 10 pg/mL (Figure 3B); thus, the method is 100-fold more sensitive than conventional ELISA. Relative diffusivity decreased by 2-fold from 1 ng/mL to 500 ng/mL and by 5.2-fold as the concentration of BoNT/A increased from 10 pg/mL to 100 ng/mL. According to refs 35−37, the viscosities of the three matrices are approximately the same (PBS, 1.05 cP; milk, 1.49 cP; serum, 1.2−2.8 cP). Indeed, our diffusivity data showed that the viscosities of the three pure matrices have no significant differences (Supporting Information Figure S2). Thus, our detection approach is highly adaptable and selective toward its targets. Examination of the Biotoxin Activity with NanoImmunosensors. Compared with the activity of toxic proteins previously detected, biotoxin activity is a more critical consideration in the quality of cosmetics and food products. Thus, a common cosmetic botulinum toxin, BOTOX, was used as a biotoxin source to evaluate toxin activities under different conditions. During measurement, 100 U of the toxin protein was prepared in three conditions, namely, active, inactive, and degraded. The toxin suspension for detection was buffered with PBS, the toxin protein was inactivated by formaldehyde treatment for 3 h, and degradation of botulinum toxin was achieved by incubation at room temperature for 24 h. The\nparticles were conjugated with full-length SNAP25 antibody, and the recombinant SNAP-25 protein was bound to the antibody−particle complex. After binding, the complex was incubated under different toxin conditions for 3 h at 30 °C to cleave the SNAP-25 protein. The cleaved forms of SNAP25137−206 antibody-conjugated AuNPs were then added to the different antibody−particle complex solutions, and the diffusivities of the three samples were calculated using the proposed measurement platform. The diffusivity of the active toxin was lower than those of the inactive and degraded toxin groups (Figure 4A). The results obtained through bead-based immunoassay were confirmed by Western blot, which showed a marked increase in cleaved SNAP-25 in the active toxin group (Figure 4A). To verify the feasibility of toxin activity assay in different\nsample matrices, we separately incubated the toxin in milk and serum and then detected the resulting mixture using our platform. For toxin inactivity measurements, 100 U of toxin protein was resuspended in 3% milk or 1% serum with a buffer medium of 0.01 M NaOH and incubated for 0, 12, 24, or 48 h at room temperature. The toxin activities in milk and serum progressively decreased with time (Figures 4B and C). A considerable increase in diffusivity was observed at 24 h. The diffusivity of toxin activity in serum increased by 3-fold at 24 h, whereas that in milk increased by 3.4-fold at 24 h. The trends observed explicitly show that the toxin suspended in milk exhibits a relatively faster degradation rate than that suspended in serum. This difference is attributed to the high protease content of milk; serum is protease free. The results are corroborated by the finding that this activity assays were easily developed upon the nano-immunosensors and were adapted\nDOI: 10.1021/acssensors.9b00644 ACS Sens. XXXX, XXX, XXX−XXX\nE\nfor different needs providing an advantage over the toxin activity assay. Quantification of Toxin Concentration and Activity in Different Commercial BoNT/A Products. The feasibility of our nano-immunosensors was verified in complex pharmaceutical excipient mixtures (NaCl and human serum albumin). Here, BOTOX and Dysport were used as test samples. BOTOX and Dysport consist of different complexing proteins. For example, Botox contains 900 kDa complex neurotoxins38 while Dysport comprises a mixture of L complex (600 kDa) and M complex (300 kDa).39 Thus, in this study, we conducted detection in pharmaceutical excipient mixtures. Diffusivity was analyzed by our nano-immunosensors and found to statistically differ between the two samples; more specifically, the diffusivity of Dysport is lower than that of BOTOX. This finding indicates that the neurotoxin concentration in the former is higher than that of the latter (Figure 5A), consistent with a recent study reporting that the mean concentrations of BoNT/A in Botox and Dysport are 0.73 and 3.5 ng/vial,40 respectively. According to the diffusivity results, the presence of another protein in the sample does not influence toxin detection. To determine toxin activity in different neurotoxin products, we incubated SNAP-25conjugated particles with different neurotoxins for 3 h at 30 °C to digest the SNAP-25 protein. After incubation, we combined SNAP25137−206 antibody-conjugated AuNPs with the particles and measured the concentration of the cleaved SNAP-25 form. Although BOTOX exhibited lower toxin protein concentrations, toxin activity was not considerably different between the two products (Figure 5B). The most common dose-equivalence ratios between BOTOX and Dysport in clinical practice are 1:3 or 1:4.41,42 Thus, the concentration of total toxin protein is not related to toxin activity.\n■ CONCLUSION In this study, we designed nano-immunosensors to quantify the concentration and activity of target toxin proteins in three matrices, namely, PBS, milk, and serum. The assays described in this study are unique compared with immunoassays using fluorescent microbeads or AuNPs to measure protein concentration because botulism neurotoxin activity is detected by Brownian motion. The sensitivity of the proposed immunosensing platform was excellent at 10 pg/mL, and its sensitivity and specificity were comparable with those of conventional ELISA. In addition, this assay requires only 2 min to complete the measurement and does not require highly\ntrained laboratory staff to measure toxin activity. Brownian motion coupled with bead-based immunoassay can overcome the limitations of existing techniques to detect botulism toxin. The proposed detection system provides a simple, robust, and highly specific immunoassay without the need for expensive and specialized equipment. Ultimately, we aim to provide a powerful biosensor for food safety in the food and medical instrument industries.\n■ ASSOCIATED CONTENT *S Supporting Information The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acssensors.9b00644.\nDetermination of protein concentration and activity in the study was dependent on the slope of the temporal diffusivity. In PBS, milk, and serum matrices, the diffusivity had no significant differences between each other. In addition, representative particle images prove that no serious aggregation was observed in the three sample matrices, either. (PDF)\n■ AUTHOR INFORMATION Corresponding Author *E-mail: oswaldchuang@mail.ncku.edu.tw."
    }, {
      "heading" : "ORCID",
      "text" : "Han-Sheng Chuang: 0000-0002-7257-6565"
    }, {
      "heading" : "Notes",
      "text" : "The authors declare no competing financial interest.\n■ ACKNOWLEDGMENTS This work was funded by the Ministry of Science and Technology under the grant 107-2622-E-006-022-CC2.\n■ REFERENCES (1) Havelaar, A. H.; Kirk, M. D.; Torgerson, P. R.; Gibb, H. J.; Hald, T.; Lake, R. J.; Praet, N.; Bellinger, D. C.; De Silva, N. R.; Gargouri, N.; et al. World Health Organization global estimates and regional comparisons of the burden of foodborne disease in 2010. PLoS medicine 2015, 12 (12), No. e1001923. (2) Oliver, S. P.; Jayarao, B. M.; Almeida, R. A. Foodborne pathogens in milk and the dairy farm environment: food safety and public health implications. Foodborne Pathog. Dis. 2005, 2 (2), 115− 129. (3) Van de Venter, T. Emerging food-borne diseases: a global responsibility. Food Nutrit. Agric. 2000, No. 26, 4−13.\nDOI: 10.1021/acssensors.9b00644 ACS Sens. XXXX, XXX, XXX−XXX\nF\n(4) Marucheck, A.; Greis, N.; Mena, C.; Cai, L. Product safety and security in the global supply chain: Issues, challenges and research opportunities. Journal of Operations Management 2011, 29 (7−8), 707−720. (5) Vilkhu, K.; Mawson, R.; Simons, L.; Bates, D. Applications and opportunities for ultrasound assisted extraction in the food industry A review. Innovative Food Sci. Emerging Technol. 2008, 9 (2), 161− 169. (6) Sharma, A. Mycotoxins: risk evaluation and management in radiation-processed foods, In Mycotoxins in Agriculture and Food Safety, Sinha, K. K.; Bhatnagar, D., Eds.; Marcel Dekker Inc: New York, 1998; pp 435−57. (7) Cliver, D. O.; Potter, M.; Riemann, H. P. Foodborne infections and intoxications; Elsevier: 2011. (8) Le Loir, Y.; Baron, F.; Gautier, M. Staphylococcus aureus and food poisoning. Genet Mol. Res. 2003, 2 (1), 63−76. (9) Chin, J. Control of communicable diseases manual, 17th ed.; American Public Health Association: Washington, DC, 2000; p 624. (10) Cote,́ T. R.; Mohan, A. K.; Polder, J. A.; Walton, M. K.; Braun, M. M. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J. Am. Acad. Dermatol. 2005, 53 (3), 407−415. (11) Münchau, A.; Bhatia, K. Regular review: Uses of botulinum toxin injection in medicine today. BMJ: British Medical Journal 2000, 320 (7228), 161. (12) Carruthers, J.; Carruthers, A. The evolution of botulinum neurotoxin type A for cosmetic applications. Journal of Cosmetic and Laser Therapy 2007, 9 (3), 186−192. (13) Montecucco, C.; Schiavo, G. Mechanism of action of tetanus and botulinum neurotoxins. Mol. Microbiol. 1994, 13 (1), 1−8. (14) Lacy, D. B.; Tepp, W.; Cohen, A. C.; DasGupta, B. R.; Stevens, R. C. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 1998, 5 (10), 898. (15) Blasi, J.; Chapman, E. R.; Link, E.; Binz, T.; Yamasaki, S.; De Camilli, P.; Südhof, T. C.; Niemann, H.; Jahn, R. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993, 365 (6442), 160. (16) Pirazzini, M.; Rossetto, O.; Eleopra, R.; Montecucco, C. Botulinum neurotoxins: Biology, pharmacology, and toxicology. Pharmacol. Rev. 2017, 69 (2), 200−235. (17) Field, M.; Cummins, J.; Mir, I.; Splevins, A.; Hooker, A. HPLC analysis of recombinant botulinum neurotoxins: Expanding the analytic toolbox. Toxicon 2016, 123 (123), S28−S29. (18) Wang, D.; Baudys, J.; Krilich, J.; Smith, T. J.; Barr, J. R.; Kalb, S. R. A two-stage multiplex method for quantitative analysis of botulinum neurotoxins type A, B, E, and F by MALDI-TOF mass spectrometry. Anal. Chem. 2014, 86 (21), 10847−10854. (19) Singh, A.; Datta, S.; Sachdeva, A.; Maslanka, S.; Dykes, J.; Skinner, G.; Burr, D.; Whiting, R. C.; Sharma, S. K. Evaluation of an enzyme-linked immunosorbent assay (ELISA) kit for the detection of botulinum neurotoxins A, B, E, and F in selected food matrices. Health security 2015, 13 (1), 37−44. (20) Splevins, A.; Field, M.; Mir, I.; Hooker, A. Informed manufacturing process development of a recombinant botulinum neurotoxin through the use of a sensitive and reproducible sandwich elisa. Toxicon 2016, 123, S78. (21) Pearce, L. B.; Borodic, G. E.; First, E. R.; MacCallum, R. D. Measurement of botulinum toxin activity: evaluation of the lethality assay. Toxicol. Appl. Pharmacol. 1994, 128 (1), 69−77. (22) Jay, J. M. Bioassay and Related Methods. In Modern food microbiology; Springer: 2000; pp 237−249. (23) Pellett, S.; Tepp, W. H.; Clancy, C. M.; Borodic, G. E.; Johnson, E. A. A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies. FEBS Lett. 2007, 581 (25), 4803−4808. (24) Hatch, A.; Kamholz, A. E.; Hawkins, K. R.; Munson, M. S.; Schilling, E. A.; Weigl, B. H.; Yager, P. A rapid diffusion immunoassay in a T-sensor. Nat. Biotechnol. 2001, 19 (5), 461−465.\n(25) Forbes, T. P.; Munson, M. S.; Forry, S. P. Theoretical analysis of a magnetophoresis-diffusion T-sensor immunoassay. Lab Chip 2013, 13 (19), 3935−3944. (26) Gaster, R. S.; Xu, L.; Han, S.-J.; Wilson, R. J.; Hall, D. A.; Osterfeld, S. J.; Yu, H.; Wang, S. X. Quantification of protein interactions and solution transport using high-density GMR sensor arrays. Nat. Nanotechnol. 2011, 6 (5), 314−320. (27) Gupta, S.; Huda, S.; Kilpatrick, P. K.; Velev, O. D. Characterization and Optimization of Gold Nanoparticle-Based Silver-Enhanced Immunoassays. Anal. Chem. 2007, 79 (10), 3810− 3820. (28) Chung, C.-Y.; Wang, J.-C.; Chuang, H.-S. Rapid bead-based antimicrobial susceptibility testing by optical diffusometry. PLoS One 2016, 11 (2), No. e0148864. (29) Chen, C.-J.; Chen, W.-L.; Phong, P. H.; Chuang, H.-S. Investigation of Micro-volume Viscosity with Janus Microbeads Based on Rotational Brownian Motion. Sensors 2019, 19 (5), 1217. (30) Wang, J.-C.; Chi, S.-W.; Shieh, D.-B.; Chuang, H.-S. Development of a self-driving bioassay based on diffusion for simple detection of microorganisms. Sens. Actuators, B 2019, 278, 140−146. (31) Wang, J.-C.; Chi, S.-W.; Yang, T.-H.; Chuang, H.-S. Label-Free Monitoring of Microorganisms and Their Responses to Antibiotics Based on Self-Powered Microbead Sensors. ACS Sensors 2018, 3 (10), 2182−2190. (32) Chung, C.-Y.; Wang, J.-C.; Chuang, H.-S. Simultaneous and quantitative monitoring of co-cultured Pseudomonas aeruginosa and Staphylococcus aureus with antibiotics on a diffusometric platform. Sci. Rep. 2017, 7, 46336. (33) Einstein, A. Investigations on the Theory of the Brownian Movement; Courier Corporation: 1956. (34) Chuang, H.-S.; Chen, Y.-J.; Cheng, H.-P. Enhanced diffusometric immunosensing with grafted gold nanoparticles for detection of diabetic retinopathy biomarker tumor necrosis factor-α. Biosens. Bioelectron. 2018, 101, 75−83. (35) Imran, M.; Khan, H.; Hassan, S. S.; Khan, R. Physicochemical characteristics of various milk samples available in Pakistan. J. Zhejiang Univ., Sci., B 2008, 9 (7), 546−551. (36) Yeom, E.; Kang, Y. J.; Lee, S.-J. Changes in velocity profile according to blood viscosity in a microchannel. Biomicrofluidics 2014, 8 (3), 034110−0341100000. (37) Booker, K. J. Critical Care Nursing: Monitoring and Treatment for Advanced Nursing Practice; Wiley-Blackwell: 2015. (38) Schantz, E. J.; Johnson, E. A. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiology and Molecular Biology Reviews 1992, 56 (1), 80−99. (39) Panjwani, N.; O’Keeffe, R.; Pickett, A. Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use. Botulinum Journal 2008, 1 (1), 153−166. (40) Frevert, J. Content of botulinum neurotoxin in botox®/ vistabel®, dysport®/azzalure®, and xeomin®/bocouture®. Drugs R&amp;D 2010, 10 (2), 67−73. (41) Marchetti, A.; Magar, R.; Findley, L.; Larsen, J. P.; Pirtosek, Z.; Råuzǐzǩa, E.; Jech, R.; Sławek, J.; Ahmed, F. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study. Mov. Disord. 2005, 20 (8), 937−944. (42) Ranoux, D.; Gury, C.; Fondarai, J.; Mas, J.; Zuber, M. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J. Neurol., Neurosurg. Psychiatry 2002, 72 (4), 459−462.\nDOI: 10.1021/acssensors.9b00644 ACS Sens. XXXX, XXX, XXX−XXX\nG"
    } ],
    "references" : [ {
      "title" : "Emerging food-borne diseases: a global responsibility",
      "author" : [ "T. Van de Venter" ],
      "venue" : "Food Nutrit. Agric",
      "citeRegEx" : "Venter,? \\Q2000\\E",
      "shortCiteRegEx" : "Venter",
      "year" : 2000
    }, {
      "title" : "Applications and opportunities for ultrasound assisted extraction in the food industry A review",
      "author" : [ "K. Vilkhu", "R. Mawson", "L. Simons", "D. Bates" ],
      "venue" : "Innovative Food Sci. Emerging Technol. 2008,",
      "citeRegEx" : "Vilkhu et al\\.,? \\Q2008\\E",
      "shortCiteRegEx" : "Vilkhu et al\\.",
      "year" : 2008
    }, {
      "title" : "Staphylococcus aureus and food poisoning",
      "author" : [ "Y. Le Loir", "F. Baron", "M. Gautier" ],
      "venue" : "Genet Mol. Res. 2003,",
      "citeRegEx" : "Loir et al\\.,? \\Q2003\\E",
      "shortCiteRegEx" : "Loir et al\\.",
      "year" : 2003
    }, {
      "title" : "Mechanism of action of tetanus and botulinum neurotoxins",
      "author" : [ "C. Montecucco", "G. Schiavo" ],
      "venue" : "Mol. Microbiol",
      "citeRegEx" : "Montecucco and Schiavo,? \\Q1994\\E",
      "shortCiteRegEx" : "Montecucco and Schiavo",
      "year" : 1994
    }, {
      "title" : "Bioassay and Related Methods",
      "author" : [ "J.M. Jay" ],
      "venue" : "In Modern food microbiology; Springer:",
      "citeRegEx" : "Jay,? \\Q2000\\E",
      "shortCiteRegEx" : "Jay",
      "year" : 2000
    }, {
      "title" : "A rapid diffusion immunoassay in a T-sensor",
      "author" : [ "E.A. Schilling", "B.H. Weigl", "P. Yager" ],
      "venue" : "Nat. Biotechnol",
      "citeRegEx" : "Schilling et al\\.,? \\Q2001\\E",
      "shortCiteRegEx" : "Schilling et al\\.",
      "year" : 2001
    } ],
    "referenceMentions" : [ ],
    "year" : 2019,
    "abstractText" : "Botulinum is a deadly bacterial toxin that causes neuroparalytic disease. However, appropriate tools to detect trace toxic proteins are scarce. This study presents a bead-based diffusometric technique for the rapid, simple, and quantitative detection of biological toxins. Functionalized particles called nano-immunosensors were fabricated by forming sandwiched immunocomplexes comprising Au nanoparticles (AuNPs), toxic proteins, and antibodies on fluorescent probe particles. Particle diffusivity tended to decline with increasing concentration of the target proteins. Calibration curves of purified botulinum toxins (0.01−500 ng/mL) were obtained from whole milk and bovine serum, and results suggested that measurement was independent of the background matrix. The activity of botulinum toxin was evaluated by coating synaptosomal-associated protein 25 (SNAP-25) on fluorescent probe particles. AuNP-conjugated antibodies attached to the probe particles when SNAP-25 proteins were cleaved by active botulinum. Thus, toxicity could be detected from slight changes in diffusivity. A short measurement time of 2 min and a limit of detection of 10 pg/mL were achieved. The nano-immunosensors demonstrated rapid biosensing capability and met the demands of onsite screening for food safety, medical instrument hygiene, and cosmetic surgery products.",
    "creator" : "PTC Arbortext Advanced Print Publisher 11.1.4300/W Library-x64"
  }
}